Full Press Release Details
| Corporate Relationship Department | National Stock Exchange of India Ltd. |
| BSE Limited | "Exchange Plaza" |
| Dalal Street, Fort | Bandra-Kurla Complex, Bandra (East), |
| Mumbai - 400 001 | Mumbai - 400 051 |
| Fax Nos.: 022-22723121 / 22723719 / | Fax Nos.: 022-26598120/ 26598237/ |
| 22722037 / 22722039 | 26598238 |
| Scrip Code: 500124 | Scrip Code: DRREDDY-EQ |
Please find enclosed a Press Release on
"Dr. Reddy's and RDIF commence clinical trials for Sputnik V vaccine in India."
This is for your information.
CC:- New York Stock Exchange Inc.(Stock Code :RDY)
| CONTACT | ||
| DR. REDDY'S LABORATORIES LTD. | Investor relationS | Media relationS |
| 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. | AMIT AGARWAL amita@drreddys.com (Ph: +91-40-49002135) | APARNA TEKURI aparnatekuri@drreddys.com (Ph: +91-40- 49002446) |
and RDIF commence clinical trials for Sputnik V vaccine in India
Hyderabad, India, December 1, 2020: Dr. Reddy's Laboratories
Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), and Russian Direct Investment Fund (RDIF) announced today that they have commenced
adaptive phase 2/3 clinical trials for Sputnik V vaccine in India after receiving the necessary clearance from the Central Drugs
Laboratory, Kasauli, India.This will be a multicenter and randomized controlled study, which will include safety and immunogenicity
The clinical trials are being conducted by JSS Medical Research
as the clinical research partner. Further, Dr. Reddy's has partnered with the Biotechnology Industry Research Assistance
Council (BIRAC), Department of Biotechnology (DBT) for advisory support and to use BIRAC's clinical trial centres for the
Recently, RDIF announced the second interim analysis of clinical
trial data, which showed 91.4% efficacy for the vaccine on day 28 after the first dose; vaccine efficacy over 95% 42 days after
the first dose. Currently, 40,000 volunteers are taking part in Phase III of Sputnik V clinical trials, out of which over 22,000
have been vaccinated with the first dose of the vaccine and more than 19,000 - with both the first and second doses of the
G V Prasad, Co-chairman and Managing Director, Dr. Reddy's
Laboratories said, "This is another significant step as we continue to collaborate with multiple entities along with the
government bodies to fast-track the process for launching the vaccine in India. We are working towards making the vaccine available
with a combination of import and indigenous production model."
In September 2020, Dr. Reddy's and RDIF entered into a
partnership to conduct clinical trials of the Sputnik V vaccine and the rights for distribution of the first 100 million doses
On August 11, 2020, the Sputnik V vaccine developed by the Gamaleya
National Research Institute of Epidemiology and Microbiology was registered by the Ministry of Health of Russia and became the
World's first registered vaccine against COVID-19 based on the human adenoviral vector platform.
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed
to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services &
Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services
including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas
of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates
in markets across the globe. Our major markets include - USA, India, Russia & CIS countries, and Europe. For more information,
log on to: www.drreddys.com
Disclaimer: This press release
may include statements of future expectations and other forward-looking statements that are based on the management's current
views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events
to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by
reason of context, the words "may", "will", "should", "expects", "plans", "intends",
"anticipates", "believes", "estimates", "predicts", "potential", or "continue"
and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those
in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit
defaults , currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality
and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and
regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including
related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our
customers', products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread
illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the
Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements"
sections of our Annual Report on Form 20-F for the year ended March 31, 2020. The company assumes no obligation to update any information